# CYFENDUS (AV7909) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/av7909

> The FDA approved CYFENDUS (AV7909), sponsored by Emergent BioSolutions Inc. (EBS), on Jul 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CYFENDUS (AV7909) |
| Codes | AV7909 |
| Sponsor | Emergent BioSolutions Inc. (EBS) https://sec-api.dev/companies/ebs/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Jul 2023: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-09-05, last confirmed 2026-09-01.
- Press release filed with the SEC (EX-99) (accession 0001367644-26-000088): "CYFENDUS® was approved by the U.S. Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age when given with recommended antibacterial drugs." https://www.sec.gov/Archives/edgar/data/1367644/000136764426000088/a08182026contractmodpr.htm
- Press release filed with the SEC (EX-99) (accession 0001367644-25-000183): "CYFENDUS® vaccine was approved by the U.S. Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age when given with recommended antibacterial drugs." https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/a09022025cyfenduspressrele.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/av7909.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CYFENDUS (AV7909) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/av7909

```bibtex
@misc{secapidev_pdufa_av7909_20261116,
  title        = {CYFENDUS (AV7909) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/av7909}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_av7909_20261116","title":"CYFENDUS (AV7909) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/av7909","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
